Ihre Abzeichen 52W-Spanne $123–$186 32% of range Analystenbewertung BUY 36 analysts Kursziel $208 +45% upside P/E 21.0 ROE 22.1% Nettogewinnmarge 20.9%

NBIX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne

03
Kurs $143.18
Marktkapitalisierung (MRQ) $14.55B
P/E (TTM) 21.0
EPS (TTM) $6.83
Umsatz (TTM) $3.37B
ROE (TTM) 22.1%
52W-Spanne $123–$186

NBIX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen

04
Spanne
Balken

Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.

Über Neurocrine Biosciences, Inc. - Common Stock Unternehmensübersicht von Wikipedia

05 · wikidata

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

History

Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.

In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.

In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.

In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.

In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.

Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.

On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.

In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.

In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.

In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.

In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.

In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.

Product pipeline

Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids

Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease

NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist

NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.

Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗

Wikidata ↗

SektorHealthcare BrancheBiotechnology Mitarbeiter2.500 LandUS

10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends

06
Umsatz$2.86B
2016-12-31 → 2025-12-31
EPS$4.67
2016-12-31 → 2025-12-31
Freier Cashflow$749M
2016-12-31 → 2025-12-31
Nettogewinnmarge20.9%
2016-12-31 → 2025-12-31
Bewertung & Kennzahlen 07–12

Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?

Kennzahl 5-Jahres-Trend NBIX 5-Jahres-Durchschnitt Peer-Median Fazit
P/E (TTM) 21.05-Jahres-Durchschnitt ≈58.9 ≈58.9 19.4 Überbewertet
P/S (TTM) 4.35-Jahres-Durchschnitt ≈6.5 ≈6.5 7.3 Unterbewertet
K/B (MRQ) 3.95-Jahres-Durchschnitt ≈5.6 ≈5.6 14.5 Unterbewertet
Kurs / FCF (TTM) 16.75-Jahres-Durchschnitt ≈29.9 ≈29.9 · ·
Kurs / Cashflow (TTM) 16.25-Jahres-Durchschnitt ≈28.0 ≈28.0 13.6 Überbewertet
Kurs / Materieller Buchwert (MRQ) 9.95-Jahres-Durchschnitt ≈5.7 ≈5.7 · ·
PEG Ratio (PEG-Ratio) ≈9.0 · · ·

Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.

Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median

Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum

14
Durchschn. Überraschung 11.3%
Nächster Bericht Okt 26, 2026
ZeitraumBerichtEPS ActualEPS est.Überraschung
30. Juni 2026 Jul 28, 2026 $1.39 $1.37 1.5%
31. März 2026 $1.91 $1.20 59.5%
31. Dezember 2025 $1.91 $1.20 59.5%
30. September 2025 $2.04 $1.62 26.1%
30. Juni 2025 $1.06 $0.99 7.0%
31. März 2025 $0.08 $0.56 -85.6%

Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow

15
Gewinn- und Verlustrechnung 17
Kennzahl Trend 202520242023202220212020201920182017201620152014
Revenue $2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788M$451M$162M$15M$20M$0
Cost of Revenue $52M$34M$40M$23M$14M$10M·$5M$1M$0$0·
R&D Expense ·······$161M$122M$94M$81M$46M
SG&A Expense $1.16B$1.01B$888M$753M$583M$433M$354M$249M$170M$68M$32M$18M
Operating Expenses $2.24B$1.78B$1.64B$1.24B$1.03B$883M$716M$414M$293M$162M$114M$64M
Operating Income $619M$570M$251M$249M$102M$163M$72M$37M$-131M$-147M$-94M$-64M
Interest Expense ··$5M$7M$26M$33M$32M$30M$20M$0$0·
Interest Income ·········$3M$2M$629.0K
Other Non-op $86M$-84M$81M$-35M$-1M$-56M$-26M$-15M$-11M$6M$20.0K$18.0K
Pretax Income $705M$486M$332M$214M$101M$107M$46M$22M$-143M$-141M··
Income Tax $227M$145M$82M$59M$12M$-301M$10M$700.0K$0$0$0$0
Net Income $479M$341M$250M$154M$90M$407M$37M$21M$-143M$-141M$-89M$-61M
EPS (Basic) $4.81$3.40$2.56$1.61$0.95$4.38$0.40$0.23$-1.62$-1.63$-1.05$-0.81
EPS (Diluted) $4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63$-1.05$-0.81
Shares (Basic) 99,500,000100,400,00097,700,00095,800,00094,600,00093,100,00091,600,00090,200,00088,089,00086,713,00084,496,00074,577,000
Shares (Diluted) 102,500,000103,700,000101,000,00098,900,00097,900,00097,800,00095,700,00095,400,00088,089,00086,713,00084,496,00074,577,000
EBITDA $619M$570M$251M$249M$102M$163M$72M$37M$-131M$-147M·$-64M
Bilanz 28
Kennzahl Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $713M$233M$251M$263M$341M$187M$112M$142M$255M$83M$74M$31M
Short-term Investments ····$370M$614M$558M$509M$261M$224M$305M$163M
Receivables $687M$479M$439M$350M$186M$157M$127M$57M$31M$0··
Inventory $69M$57M$38M$35M$30M$28M$17M$11M$1M$0··
Prepaid Expense $171M$48M··········
Other Current Assets $116M$64M$98M$79M$46M$30M$17M$19M$7M$3M$5M$4M
Current Assets $2.52B$1.72B$1.61B$1.45B$973M$1.02B$831M$738M$555M$310M$384M$198M
PP&E (Net) $90M$83M$71M$59M$59M$45M$42M$34M$11M$6M$3M$3M
PP&E (Gross) $208M$189M$154M$125M$110M$86M$76M$62M$38M$32M$30M$31M
Accum. Depreciation $118M$106M$83M$66M$52M$42M$34M$28M$28M$26M$27M$29M
Goodwill $6M$6M$6M$5M$0·······
Intangibles $5M$36M$36M$37M$0·······
Other Non-current Assets $49M$52M$50M$25M$4M$6M$0·····
Total Assets $4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993M$818M$365M$475M$243M
Accounts Payable $674M$462M$449M$348M$226M$169M$141M$86M$6M$5M$3M$246.0K
Accrued Liabilities ·········$21M$19M$12M
Current Liabilities $743M$508M$655M$538M$246M$186M$565M$88M$54M$30M$26M$16M
Capital Leases $415M$455M$258M$94M$105M$94M$87M$0····
Deferred Tax $0···········
Other Non-current Liabilities $220M$166M$106M$30M$12M$10M$17M$36M$0$113.0K$221.0K$260.0K
Total Liabilities $1.38B$1.13B$1.02B$661M$698M$608M$669M$512M$445M$50M$50M$34M
Common Stock $100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$91.0K$89.0K$87.0K$86.0K$76.0K
Paid-in Capital ···········$1.04B
Retained Earnings $448M$29M$-157M$-407M$-636M$-725M$-1.13B$-1.18B$-1.20B$-1.06B$-915M$-826M
AOCI $13M$6M$7M$-8M$-2M$2M$1M$-2M$-2M$-318.0K$-977.0K$-277.0K
Stockholders' Equity $3.25B$2.59B$2.23B$1.71B$1.37B$1.13B$637M$481M$372M$315M$424M$209M
Liabilities + Equity $4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993M$818M$365M$475M$243M
Shares Outstanding 100,100,00099,400,00098,700,00096,500,00094,900,00093,500,00092,300,00090,797,00088,793,90386,883,30086,262,59476,465,942
Cashflow 15
Kennzahl Trend 202520242023202220212020201920182017201620152014
D&A ·······$4M$2M$1M$1M$827.0K
Stock-based Comp $218M$196M$194M$173M$134M$100M$75M$58M$43M$28M$28M$10M
Deferred Tax $164M$-123M$-61M$22M$6M$-311M$0$0····
Amort. of Intangibles $4M$4M$4M$500.0K$0$0······
Operating Cash Flow $783M$595M$390M$339M$256M$228M$147M$101M$-94M$-106M$-38M$-47M
CapEx $34M$38M$28M$16M$23M$11M$15M$25M$7M$4M$2M$2M
Investing Cash Flow $-264M$-127M$-467M$-177M$-130M$4M$-211M$-243M$-251M$113M··
Stock Issued $129M$122M$65M$45M$28M$29M$32M$30M$14M$2M$277M$139M
Stock Repurchased $168M$300M$0$0········
Net Stock Activity $-38M$-178M$65M$45M$28M$29M$27M$30M$14M$2M·$139M
Financing Cash Flow $-38M$-487M$65M$-234M$27M$-158M$32M$30M$517M$2M··
Net Change in Cash $480M$-18M$-12M$-73M$154M$75M$-32M$-112M$171M$9M$43M$-14M
Taxes Paid $81M···········
Free Cash Flow $749M$557M$362M$323M$233M$218M$137M$77M$-101M$-110M·$-49M
Levered FCF ··$358M$318M$210M$92M$112M$47M····
Rentabilität 7
Kennzahl Trend 202520242023202220212020201920182017201620152014
Operating Margin 21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%··
Net Margin 16.7%14.5%13.2%10.4%7.9%38.9%4.7%4.7%-88.2%-940.6%··
Pretax Margin 24.7%20.6%17.6%14.4%8.9%10.2%5.9%4.8%····
EBITDA Margin 21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%··
ROA 11.5%9.8%8.9%7.0%4.7%26.8%3.2%2.3%-24.1%-33.6%·-30.4%
ROE 16.1%12.9%11.8%9.5%6.6%42.2%6.1%4.5%-41.5%-38.2%·-36.8%
ROIC 12.9%15.5%8.5%10.5%6.6%55.2%9.0%7.4%····
Liquidität & Solvenz 3
Kennzahl Trend 202520242023202220212020201920182017201620152014
Current Ratio 3.43.42.52.74.05.41.58.410.210.2·12.7
Quick Ratio 1.91.41.11.13.65.11.42.210.110.1·12.4
Interest Coverage ··54.535.14.05.02.31.2-6.7···
Effizienz 3
Kennzahl Trend 202520242023202220212020201920182017201620152014
Asset Turnover 0.70.70.70.70.60.70.70.50.30.0·0.0
Inventory Turnover 0.80.71.10.7···0.8····
Receivables Turnover 4.95.14.85.66.67.48.610.310.4···
Pro Aktie 5
Kennzahl Trend 202520242023202220212020201920182017201620152014
Book Value / Share $32.50$26.05$22.61$17.70$14.48$12.04$6.90$5.29$4.19$3.62·$2.73
Revenue / Share $27.91$22.71$18.68$15.05$11.58$10.69$8.23$4.73$1.83$0.17·$0.00
Cash Flow / Share $7.64$5.74$3.86$3.43$2.62$2.34$1.59$1.06$-1.07$-1.22·$-0.63
Cash / Share $7.12$2.34$2.54$2.72$3.59$2.00$1.22$1.56$2.87$0.96·$0.41
EPS (TTM) $4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63$-1.05$-0.81
Wachstumsraten 9
Kennzahl Trend 202520242023202220212020201920182017201620152014
Revenue YoY 21.4%24.8%26.8%31.3%8.4%·······
Revenue CAGR 3Y 24.3%27.6%21.7%·········
Revenue CAGR 5Y 22.3%···········
EPS YoY 41.9%33.2%58.3%69.6%-77.9%·······
EPS CAGR 3Y 44.1%52.9%-16.0%·········
EPS CAGR 5Y 2.3%···········
Net Income YoY 40.2%36.7%61.6%72.4%-78.0%·······
Net Income CAGR 3Y 45.8%56.2%-15.0%·········
Net Income CAGR 5Y 3.3%···········
Bewertung (TTM) 10
Kennzahl Trend 202520242023202220212020201920182017201620152014
Revenue TTM $2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788M$451M$162M$15M$20M$0
Net Income TTM $479M$341M$250M$154M$90M$407M$37M$21M$-143M$-141M$-89M$-61M
Market Cap $14.20B$13.57B$13.00B$11.53B$8.08B$8.96B$9.92B$6.48B$6.89B$3.36B·$1.71B
P/E 30.441.553.376.692.623.0275.6324.6-47.9-23.7-53.9-27.6
P/S 5.05.86.97.77.18.612.614.442.6224.2··
P/B 4.45.25.86.75.98.015.613.518.510.7·8.2
P / Tangible Book 4.45.35.96.95.98.0······
P / Cash Flow 18.122.833.434.031.539.265.264.0-73.0-31.7·-36.2
P / FCF 19.024.436.035.734.741.272.284.7-68.0-30.5·-35.0
Earnings Yield 3.3%2.4%1.9%1.3%1.1%4.3%0.36%0.31%-2.1%-4.2%-1.9%-3.6%

Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt

Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre

16
Kennzahl 2025-12-312024-12-312023-12-312022-12-312021-12-31
Umsatz $2.86B $2.36B $1.89B $1.49B $1.13B
Betriebsgewinnmarge % 21.6% 24.2% 13.3% 16.7% 9.0%
Nettoergebnis $479M $341M $250M $154M $90M
Verwässerte EPS $4.67 $3.29 $2.47 $1.56 $0.92

Institutionelle Eigentümer (13F) 828 Einreicher · $18.1B gesamt · Stand 30. September 2026

17

Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.

Inhaber 828
Gehaltener Wert $18.1B
Neue Positionen 148
Geschlossene Positionen 62
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
Neue Positionen Geschlossene Positionen Erhöht Abgenommen Nettoveränderung der Aktien
148 (+50 vs. Vorquartal) 62 (-36 vs. Vorquartal) 317 (+16 vs. Vorquartal) 226 (+12 vs. Vorquartal) +587K

Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.

Institution Wert Aktien % der verfolgten 13F Typ
BlackRock, Inc. $2.310.885.707 13.711.607 12,75% Aktien
VANGUARD GROUP INC $1.375.793.692 9.700.301 7,59% Aktien
JPMORGAN CHASE & CO $1.088.569.109 6.398.674 6,01% Aktien
Dodge & Cox $941.218.594 5.584.707 5,19% Aktien
VANGUARD PORTFOLIO MANAGEMENT LLC $838.307.078 4.974.083 4,63% Aktien
VANGUARD CAPITAL MANAGEMENT LLC $766.048.708 4.545.339 4,23% Aktien
STATE STREET CORP $739.126.759 4.385.598 4,08% Aktien
AQR CAPITAL MANAGEMENT LLC $643.472.716 3.818.037 3,55% Aktien
RENAISSANCE TECHNOLOGIES LLC $393.680.402 2.335.897 2,17% Aktien
GEODE CAPITAL MANAGEMENT, LLC $359.607.676 2.138.777 1,98% Aktien
TWO SIGMA INVESTMENTS, LP $349.922.479 2.076.260 1,93% Aktien
Vestal Point Capital, LP $316.845.800 1.880.000 1,75% Aktien
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $251.858.951 1.494.259 1,39% Aktien
MORGAN STANLEY $222.231.858 1.318.607 1,23% Aktien
RTW INVESTMENTS, LP $213.689.740 1.267.925 1,18% Aktien
NORTHERN TRUST CORP $212.306.405 1.259.717 1,17% Aktien
Invesco Ltd. $181.565.621 1.077.317 1,00% Aktien
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $164.200.136 974.279 0,91% Aktien
NORGES BANK $164.132.866 973.880 0,91% Aktien
FIRST TRUST ADVISORS LP $155.578.851 923.125 0,86% Aktien
DIMENSIONAL FUND ADVISORS LP $123.525.529 732.877 0,68% Aktien
JACOBS LEVY EQUITY MANAGEMENT, INC $122.375.286 726.112 0,68% Aktien
TWO SIGMA ADVISERS, LP $119.504.823 842.592 0,66% Aktien
Bank of New York Mellon Corp $117.826.993 699.125 0,65% Aktien
Swedbank AB $109.730.107 651.082 0,61% Aktien
VANGUARD FIDUCIARY TRUST CO $109.170.737 647.763 0,60% Aktien
IEQ CAPITAL, LLC $107.913.614 640.304 0,60% Aktien
GOLDMAN SACHS GROUP INC $106.495.877 631.892 0,59% Aktien
BANK OF AMERICA CORP /DE/ $104.382.489 619.352 0,58% Aktien
VICTORY CAPITAL MANAGEMENT INC $104.238.729 618.499 0,58% Aktien
Man Group plc $101.292.738 601.019 0,56% Aktien
ROYAL BANK OF CANADA $98.337.000 583.476 0,54% Aktien
RAYMOND JAMES FINANCIAL INC $97.778.953 580.170 0,54% Aktien
FRANKLIN RESOURCES INC $93.211.316 553.068 0,51% Aktien
UBS Group AG $92.009.492 545.937 0,51% Aktien
Caisse de depot et placement du Quebec $91.002.327 539.961 0,50% Aktien
ARMISTICE CAPITAL, LLC $90.307.457 535.838 0,50% Aktien
AMERIPRISE FINANCIAL INC $84.660.571 502.267 0,47% Aktien
PRIMECAP MANAGEMENT CO/CA/ $82.807.988 491.340 0,46% Aktien
Hood River Capital Management LLC $79.082.184 469.233 0,44% Aktien
Nuveen, LLC $77.408.341 459.301 0,43% Aktien
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $75.318.261 571.719 0,42% Aktien
Pictet Asset Management Holding SA $72.751.030 430.635 0,40% Aktien
Rockefeller Capital Management L.P. $62.955.982 373.548 0,35% Aktien
Fiera Capital Corp $62.895.914 373.192 0,35% Aktien
Gotham Asset Management, LLC $62.622.213 371.568 0,35% Aktien
JANUS HENDERSON GROUP PLC $61.515.240 466.977 0,34% Aktien
ALLIANCEBERNSTEIN L.P. $60.767.710 461.270 0,34% Aktien
Vinva Investment Management Ltd $58.838.530 346.109 0,32% Aktien
AustralianSuper Pty Ltd $58.817.535 348.993 0,32% Aktien

Alle 828 institutionellen Eigentümer anzeigen →

Aktivisten & 5%+-Eigentümer 1 Beteiligung

18

Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.

Anmelder Eingereicht Beteiligung Status Zweck Einreichung
Neurocrine Biosciences, Inc. ×3 Einreichungen 24. Februar 2023 · Erste Einreichung · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Unternehmensinsider 41 Insider · 22 Führungskräfte · 15 Direktoren

19
Insider Rolle Letzte Aktivität Gehaltene Aktien Käufe 12m Verkäufe 12m Netto 12m
Kyle Gano Chief Executive Officer 11. September 2026 F 154.728 0 3 $-4.872.890
Matt Abernethy Chief Financial Officer 14. September 2026 S 42.808 0 1 $-363.289
Timothy Coughlin Chief Financial Officer 6. Februar 2017 S 137.961 0 0 $0
David-Alexandre C Gros President & COO 6. Februar 2017 A · 0 0 $0
David W. Boyer Chief Corp. Affairs Officer 14. September 2026 S 8.722 0 2 $-739.070
Ingrid Delaet Chief Regulatory Officer 11. September 2026 F 18.289 0 5 $-3.747.962
Jude Onyia Chief Scientific Officer 11. September 2026 F 22.647 0 2 $-3.473.580
Sanjay Chandru Keswani Chief Medical Officer 11. September 2026 F 3.281 0 0 $0
Julie Cooke Chief Human Resources Officer 11. September 2026 F 24.025 0 5 $-5.770.377
Eric Benevich Chief Commercial Officer 11. September 2026 F 67.297 0 2 $-1.238.918
Darin Lippoldt Chief Legal Officer 11. September 2026 F 56.793 0 5 $-4.196.071
Eiry Roberts Chief Medical Officer 13. Februar 2025 M 35.640 0 0 $0
Malcolm Lloyd-Smith Chief Integration Officer 8. Februar 2023 S 42.337 0 0 $0
Dimitri E. Grigoriadis Chief Research Officer 31. Januar 2022 A 82.273 0 0 $0
Haig P. Bozigian Chief Development Officer 8. Februar 2021 A 157.651 0 0 $0
Christopher Flint Obrien Former Chief Medical Officer 5. Februar 2018 A 55.946 0 0 $0
VALEUR JENSEN MARGARET E EVP and General Counsel 31. August 2011 A 118.256 0 0 $0
Richard J Ranieri Sr. VP, Human Resources 27. Februar 2008 A 9.667 0 0 $0
Wendall Wierenga EVP, Research & Development 19. Januar 2006 A 5.023 0 0 $0
Henry Pan Executive VP and CMO 3. Juni 2005 A 11.216 0 0 $0
Robert J Little SVP, Commercial Operations 18. Februar 2005 A · 0 0 $0
SAUNDERS JOHN Vice President Research (Chem) 18. Dezember 2003 S 7.966 0 0 $0
Kevin Charles Gorman Direktor 11. September 2026 F 517.797 0 1 $-37.824.431
SHERWIN STEPHEN A Direktor 2. September 2026 G 14.860 0 5 $-4.132.990
Leslie V Norwalk Direktor 29. Juli 2026 M 2.430 0 5 $-1.973.882
Johanna Mercier Direktor 27. Mai 2026 A 6.853 0 0 $0
William H Rastetter Direktor 27. Mai 2026 A 43.678 0 1 $-2.732.760
Christine A Poon Direktor 27. Mai 2026 A 4.753 0 0 $0
POPS RICHARD F Direktor 27. Mai 2026 A 37.798 0 1 $-2.364.750
LYONS GARY A Direktor 27. Mai 2026 A 122.141 0 1 $-2.289.150
MORROW GEORGE J Direktor 27. Mai 2026 A 10.386 0 1 $-2.150.550
Alfred Sandrock Direktor 22. Mai 2019 A · 0 0 $0
Corinne H Nevinny Direktor 24. Mai 2018 A 43.283 0 0 $0
Thomas W Mitchell Direktor 28. Mai 2015 A 1.000 0 0 $0
VALE WYLIE W Direktor 25. Mai 2011 A 231.372 0 0 $0
Adrian Adams Direktor 30. Juni 2006 A · 0 0 $0
Shalini Sharp · 27. Mai 2026 A 4.088 0 0 $0
MOLLICA JOSEPH A · 22. Mai 2017 A 56.042 0 0 $0
HAWRAN PAUL W · 18. September 2006 J 132.000 0 0 $0
Lawrence Steinman · 2. März 2005 S 15.500 0 0 $0
CONLON PAUL J · 16. Dezember 2003 S 57.335 0 0 $0

Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten

ETF-Besitz Gehalten von 104 ETFs

20

Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.

Fonds Gewicht Anteile Stand Quelle
IBRN · iShares Trust 3,75% 1.793 SH 11. September 2026 Täglich
MCOW · Pacer Funds Trust 2,57% 164 NS 31. Juli 2026 N-PORT
PBE · Invesco Exchange-Traded Fund Trust 2,56% 76.511 SH 1. Oktober 2026 Täglich
BUL · Pacer Funds Trust 2,15% 16.896 NS 31. Juli 2026 N-PORT
CVSM · Elevation Series Trust 2,04% 11.525 NS 31. Juli 2026 N-PORT
POWA · Invesco Exchange-Traded Self-Indexe… 1,96% 22.570 SH 1. Oktober 2026 Täglich
JMID · Janus Detroit Street Trust 1,93% 2.742 NS 31. Juli 2026 N-PORT
FGSI · First Trust Exchange-Traded Fund IV 1,90% 236 NS 31. Juli 2026 N-PORT
ABOT · Abacus FCF ETF Trust 1,90% 460 NS 31. Juli 2026 N-PORT
XMHQ · Invesco Exchange-Traded Fund Trust 1,77% 667.778 SH 1. Oktober 2026 Täglich
FXH · First Trust Exchange-Traded AlphaDE… 1,67% 105.135 NS 31. Juli 2026 N-PORT
GRPM · Invesco Exchange-Traded Fund Trust 1,64% 56.706 SH 1. Oktober 2026 Täglich
BBP · ETFis Series Trust I 1,44% 8.494 NS 31. Juli 2026 N-PORT
CSMD · Professionally Managed Portfolios 1,18% 32.094 NS 31. Juli 2026 N-PORT
IBB · iShares Trust 1,14% 755.021 SH 11. September 2026 Täglich
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… 1,11% 7.516 NS 31. Juli 2026 N-PORT
RFG · Invesco Exchange-Traded Fund Trust 1,06% 24.859 SH 1. Oktober 2026 Täglich
JSMD · Janus Detroit Street Trust 1,05% 66.455 NS 31. Juli 2026 N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust … 0,94% 7.190 SH 1. Oktober 2026 Täglich
IVOG · VANGUARD ADMIRAL FUNDS 0,89% 99.214 SH 19. August 2026 Täglich
COWG · Pacer Funds Trust 0,78% 103.520 NS 31. Juli 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 0,73% 399 NS 31. Juli 2026 N-PORT
QQQJ · Invesco Exchange-Traded Fund Trust … 0,73% 59.895 SH 1. Oktober 2026 Täglich
LSEQ · Harbor ETF Trust 0,72% 661 NS 31. Juli 2026 N-PORT
LABU · Direxion Shares ETF Trust 0,71% 20.978 NS 31. Juli 2026 N-PORT
IQSM · New York Life Investments ETF Trust 0,63% 12.528 NS 31. Juli 2026 N-PORT
FNY · First Trust Exchange-Traded AlphaDE… 0,63% 21.784 NS 31. Juli 2026 N-PORT
QLV · FlexShares Trust 0,56% 5.460 NS 31. Juli 2026 N-PORT
ISCG · iShares Trust 0,52% 31.868 SH 11. September 2026 Täglich
PTMC · Pacer Funds Trust 0,47% 11.072 NS 31. Juli 2026 N-PORT
QVMM · Invesco Exchange-Traded Fund Trust … 0,46% 13.252 SH 1. Oktober 2026 Täglich
USMV · iShares Trust 0,46% 697.795 SH 11. September 2026 Täglich
VBK · VANGUARD INDEX FUNDS 0,46% 1.331.820 SH 19. August 2026 Täglich
IVOO · VANGUARD ADMIRAL FUNDS 0,46% 162.408 SH 19. August 2026 Täglich
SMDX · Tidal Trust III 0,43% 3.374 NS 31. Juli 2026 N-PORT
BKMC · BNY Mellon ETF Trust 0,42% 16.429 NS 31. Juli 2026 N-PORT
IWP · iShares Trust 0,39% 480.949 SH 11. September 2026 Täglich
SDG · iShares Trust 0,38% 4.071 SH 11. September 2026 Täglich
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0,36% 44.021 NS 31. Juli 2026 N-PORT
MIDU · Direxion Shares ETF Trust 0,36% 1.476 NS 31. Juli 2026 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0,31% 46.187 NS 31. Juli 2026 N-PORT
FNX · First Trust Exchange-Traded AlphaDE… 0,30% 24.447 NS 31. Juli 2026 N-PORT
JPME · J.P. Morgan Exchange-Traded Fund Tr… 0,29% 8.053 NS 31. Juli 2026 N-PORT
COWZ · Pacer Funds Trust 0,25% 283.150 NS 31. Juli 2026 N-PORT
IYH · iShares Trust 0,25% 57.843 SH 11. September 2026 Täglich
VHT · VANGUARD WORLD FUND 0,24% 286.599 SH 19. August 2026 Täglich
FHLC · FIDELITY COVINGTON TRUST 0,23% 45.259 NS 31. Juli 2026 N-PORT
SMMD · iShares Trust 0,21% 52.744 SH 11. September 2026 Täglich
EUSA · iShares, Inc. 0,20% 25.089 SH 11. September 2026 Täglich
VB · VANGUARD INDEX FUNDS 0,20% 2.306.077 SH 19. August 2026 Täglich
PWS · Pacer Funds Trust 0,20% 287 NS 31. Juli 2026 N-PORT
SIZE · iShares Trust 0,20% 5.417 SH 11. September 2026 Täglich
VXF · VANGUARD INDEX FUNDS 0,19% 1.153.763 SH 19. August 2026 Täglich
FAD · First Trust Exchange-Traded AlphaDE… 0,19% 6.541 NS 31. Juli 2026 N-PORT
ACWV · iShares, Inc. 0,18% 37.854 SH 11. September 2026 Täglich
RWK · Invesco Exchange-Traded Fund Trust … 0,13% 11.381 SH 1. Oktober 2026 Täglich
IWR · iShares Trust 0,11% 405.396 SH 11. September 2026 Täglich
FHEQ · Fidelity Greenwood Street Trust 0,11% 6.157 NS 31. Juli 2026 N-PORT
ESUM · Strategy Shares 0,10% 1.133 NS 31. Juli 2026 N-PORT
HEQQ · J.P. Morgan Exchange-Traded Fund Tr… 0,10% 177 NS 31. Juli 2026 N-PORT
LRND · New York Life Investments ETF Trust 0,10% 2.270 NS 31. Juli 2026 N-PORT
EQAL · Invesco Exchange-Traded Fund Trust … 0,09% 4.819 SH 1. Oktober 2026 Täglich
HELO · J.P. Morgan Exchange-Traded Fund Tr… 0,09% 23.838 NS 31. Juli 2026 N-PORT
DFUV · Dimensional ETF Trust 0,08% 70.759 NS 31. Juli 2026 N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe… 0,07% 23.694 SH 1. Oktober 2026 Täglich
DYNF · BlackRock ETF Trust 0,07% 177.312 SH 11. September 2026 Täglich
USXF · iShares Trust 0,06% 5.665 SH 11. September 2026 Täglich
ESMV · iShares Trust 0,05% 26 SH 11. September 2026 Täglich
GARP · iShares Trust 0,05% 9.869 SH 11. September 2026 Täglich
DFAC · Dimensional ETF Trust 0,05% 141.631 NS 31. Juli 2026 N-PORT
DXUV · Dimensional ETF Trust 0,05% 1.484 NS 31. Juli 2026 N-PORT
DCOR · Dimensional ETF Trust 0,04% 8.569 NS 31. Juli 2026 N-PORT
IUSG · iShares Trust 0,04% 89.338 SH 11. September 2026 Täglich
IWF · iShares Trust 0,04% 320.069 SH 11. September 2026 Täglich
VONG · VANGUARD SCOTTSDALE FUNDS 0,04% 134.662 SH 19. August 2026 Täglich
ESGV · VANGUARD WORLD FUND 0,03% 22.375 SH 19. August 2026 Täglich
TILT · FlexShares Trust 0,03% 3.888 NS 31. Juli 2026 N-PORT
DFAU · Dimensional ETF Trust 0,03% 20.775 NS 31. Juli 2026 N-PORT
RECS · Columbia ETF Trust I 0,02% 8.549 NS 31. Juli 2026 N-PORT
DFUS · Dimensional ETF Trust 0,02% 28.885 NS 31. Juli 2026 N-PORT
IYY · iShares Trust 0,02% 4.355 SH 11. September 2026 Täglich
IWB · iShares Trust 0,02% 68.459 SH 11. September 2026 Täglich
ITOT · iShares Trust 0,02% 131.068 SH 11. September 2026 Täglich
IWS · iShares Trust 0,02% 20.508 SH 11. September 2026 Täglich
IWV · iShares Trust 0,02% 27.012 SH 11. September 2026 Täglich
PBUS · Invesco Exchange-Traded Fund Trust … 0,02% 16.474 SH 1. Oktober 2026 Täglich
VTI · VANGUARD INDEX FUNDS 0,02% 3.193.839 SH 19. August 2026 Täglich
VONE · VANGUARD SCOTTSDALE FUNDS 0,02% 16.227 SH 19. August 2026 Täglich
VTHR · VANGUARD SCOTTSDALE FUNDS 0,02% 8.342 SH 19. August 2026 Täglich
PRF · Invesco Exchange-Traded Fund Trust 0,02% 11.591 SH 1. Oktober 2026 Täglich
TOK · iShares Trust 0,02% 249 SH 11. September 2026 Täglich
URTH · iShares, Inc. 0,02% 8.440 SH 11. September 2026 Täglich
ACWI · iShares Trust 0,01% 30.548 SH 11. September 2026 Täglich
DFLV · Dimensional ETF Trust 0,01% 4.926 NS 31. Juli 2026 N-PORT
DFVX · Dimensional ETF Trust 0,01% 323 NS 31. Juli 2026 N-PORT
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,01% 85.082 SH 19. August 2026 Täglich
VONV · VANGUARD SCOTTSDALE FUNDS 0,01% 8.319 SH 19. August 2026 Täglich
FYEE · Fidelity Greenwood Street Trust 0,01% 110 NS 31. Juli 2026 N-PORT
REVS · Columbia ETF Trust I 0,01% 124 NS 31. Juli 2026 N-PORT
IWD · iShares Trust 0,01% 30.627 SH 11. September 2026 Täglich
IJH · iShares Trust · 3.528.125 SH 11. September 2026 Täglich
IJK · iShares Trust · 582.451 SH 11. September 2026 Täglich
XJH · iShares Trust · 13.736 SH 8. September 2026 Täglich
ISCB · iShares Trust · 4.526 SH 11. September 2026 Täglich

NBIX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial

21
Bewertung · 36 Analysten KAUF
Median-Ziel $214.00 +49,5%
14 38,9% Starker Kauf
17 47,2% Kauf
5 13,9% Halten
0 0,0% Verkauf
0 0,0% Starker Verkauf

12-Monats-Kursziel

29 Analysten · 2026-10-03

Mittelwert-Ziel $207.81 +45,1%

← Unter allen Zielen Aktueller Preis $143.18
Tief$164.00 Mittelwert$207.81 Hoch$253.00

Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen

22

FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.

Ticker Marktkapitalisierung P/E Umsatz Vj. Nettomarge ROE Bruttogewinnmarge
NBIX $14.20B 30.4 21.4% 16.7% 16.1% ·
INSM $37.29B -27.1 66.7% -210.5% -128.4% ·
INCY $19.60B 15.4 21.2% 25.0% 27.6% ·
UTHR $21.27B 17.5 10.6% 41.9% 18.7% 87.9%
EXEL $11.44B 15.7 7.0% 33.7% 37.3% ·
SMMT $13.56B -12.1 · · -235.1% ·
BBIO $14.90B -20.2 126.3% -146.0% 41.2% ·
TWST $1.71B -21.6 20.3% -20.6% -17.0% ·
HALO $7.93B 26.3 37.5% 22.7% 166.1% ·
MDGL $13.30B -45.3 432.1% -30.1% -44.4% ·

Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen

23
Optionen für Dezember 2027 jetzt verfügbar für Neurocrine Biosciences (NBIX) Nasdaq · 5 Monate, 3 Wochen vor Aktienmarkt heute, 6. April: Soleno Therapeutics steigt nach Kaufvereinbarung in Höhe von 2,9 Milliarden US-Dollar in bar Nasdaq · 5 Monate, 3 Wochen vor Neurocrine übernimmt Soleno für 2,9 Mrd. US-Dollar in bar; Soleno-Aktie steigt im vorbörslichen Handel Nasdaq · 5 Monate, 3 Wochen vor

Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis

25
BLUECHIP_DIP Stop-Loss ausgelöst Sep 8
Risiko 1 Belohnung 1,67
Einstieg $156.04 R:R 1,67
BLUECHIP_DIP Stop-Loss ausgelöst Aug 6
Risiko 1 Belohnung 2,78
Einstieg $161.50 R:R 2,78
BLUECHIP_DIP Abgelaufen Apr 28
Risiko 1 Belohnung 5,00
Einstieg $129.88 R:R 5,00
BLUECHIP_DIP Stop-Loss ausgelöst Apr 20
Risiko 1 Belohnung 4,80
Einstieg $132.67 R:R 4,80
BLUECHIP_DIP Stop-Loss ausgelöst Apr 9
Risiko 1 Belohnung 5,00
Einstieg $132.79 R:R 5,00

Derzeit kein offenes Signal – keine Karte ist ausgefüllt, und das ist ehrlich.

Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten

26

Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.

Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.

Quelle: SEC 10-Q eingereicht Jul 31, 2026